Clinical trials: Ocular Hypertension
Ocular Hypertension, Open Angle Glaucoma
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in…
- Trial name
- Constellation (NCT01707381)
- Testing
- BOL-303259-X, Timolol maleate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Ocular Hypertension
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between…
- Trial name
- NCT00383019
- Testing
- Xalatan, Xalacom
- Where
- 54 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers
The proposed trial a "Randomized, Double Blind, Placebo Controlled "first in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 in Male Healthy Volunteers" (Protocol Code No:CUNFI-1509…
- Trial name
- NCT02639975
- Testing
- PBF-677
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Evaluation of OCT Measurements
The purpose of the study is to repeatability, reproducibility and agreement of eye measurements in retina and glaucoma patients.
- Trial name
- NCT01806402
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Optovue
Cataracts, Retina Surgery
Eye Drop Application Monitor, Pilot Study
The purpose of this study is to determine if an eye drop video monitoring device can accurately assess (as compared to a patient's own log or a proprietary software) the exact amount and time of eye drop delivery to a patient's…
- Conditions
- Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
- Trial name
- NCT02639845
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Alexander Eaton
Glaucoma
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
- Trial name
- NCT00347841
- Testing
- Bimatoprost 0.03%, Latanoprost
- Where
- United States
- Sponsor
- Innovative Medical
Glaucoma
VividWhite Glaucoma Implant (VW-51) Pivotal Study
The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51…
- Trial name
- NCT06176170
- Testing
- VividWhite Glaucoma Implant (VW-51)
- Where
- 6 sites in Australia
- Volunteers
- 65 people
- Sponsor
- VividWhite Pty Ltd
Primary Open-angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351.
- Trial name
- NCT03762369
- Testing
- CKD-351, Latanoprost, D930
- Where
- South Korea
- Volunteers
- 384 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Refractive Error, Glaucoma
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products
Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.
- Conditions
- Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
- Trial name
- NCT05394324
- Testing
- Intervention
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 1,674 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
- Trial name
- NCT00150267
- Testing
- Xalacom
- Where
- 74 sites in Australia, Belgium and 10 more
- Volunteers
- 976 people
- Sponsor
- Pfizer
Open-Angle Glaucoma, Ocular Hypertension
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when…
- Trial name
- NCT00788541
- Testing
- Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
ELAZOP Switching Study in Korea
The purpose of this study is to assess the safety and efficacy of switching to ELAZOP from prior pharmacotherapy in patients with open-angled glaucoma.
- Trial name
- NCT01055366
- Testing
- Elazop (Azarga)
- Where
- 10 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Alcon Research
Glaucoma
Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients
The aim of the study is to evaluate the effectiveness and the safety of the cyclocoagulation using HIFU in glaucoma patients
- Trial name
- NCT01791673
- Testing
- Ultrasound glaucoma treatment
- Where
- 5 sites in France
- Volunteers
- 30 people
- Sponsor
- EyeTechCare
Glaucoma
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.
- Trial name
- NCT04164459
- Testing
- Xalost S, Xalatan, Taflotan-S
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Elevated Intraocular Pressure
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.
- Trial name
- NCT00902200
- Testing
- AR-12286, AR-12286 vehicle
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma
Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma
This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA)…
- Trial name
- NCT04060758
- Testing
- PA5108 Latanoprost FA SR Ocular Implant
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 37 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.